Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis
- PMID: 39326211
- DOI: 10.1016/j.vaccine.2024.126385
Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis
Abstract
Mastitis is a major issue for the dairy industry. Despite multiple attempts, the efficacy of available mastitis vaccines is limited and this has been attributed to their incapacity to trigger robust cell-mediated immunity. Yeasts have recently been identified as promising antigen vectors capable of inducing T-cell responses, surpassing the antibody-biased mechanisms elicited by conventional adjuvanted vaccines. In this study, we combine in vitro, ex vivo, and in vivo approaches to evaluate the potential of the yeast Saccharomyces cerevisiae as a platform for novel vaccines against bovine mastitis. We demonstrate that S. cerevisiae is safe for intramuscular and intramammary immunisation in dairy cows. Vaccination resulted in a significant increase of IFNγ and IL-17 responses against the yeast platform but not against the vaccine antigen. These observations highlight that strategies to counterbalance the immunodominance of S. cerevisiae antigens are necessary for the development of successful vaccine candidates.
Keywords: Bovine; Cell-mediated immunity; Mammary gland; Mastitis; Saccharomyces cerevisiae; Yeast-based vaccines.
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Rodrigo Prado Martins reports financial support, administrative support, article publishing charges, and equipment, drugs, or supplies were provided by French National Research Agency. Kamila Reis Santos reports financial support was provided by Campus France. Pablo Gomes Noleto reports financial support was provided by French National Institute for Agricultural Research INRAE. Celya Danzelle reports financial support was provided by University of Tours. Rodrigo Prado Martins has patent pending to INRAE, Université de Tours. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
